Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis.

Authors:
Ferrari S; Geddes DM; Alton EW.

Journal:
Adv Drug Deliv Rev

Publication Year: 2002

DOI:
10.1016/S0169-409X(02)00145-X

PMCID:
PMC7126523

PMID:
12458150

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Adv Drug Deliv Rev

Abbreviation: Adv Drug Deliv Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Drug Therapy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics.
Kang DD; Li H; Dong Y. (2023) - Transparency Score: 3/6
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery.
Han G; Noh D; Lee H and 4 more (2023) - Transparency Score: 3/6
Imaging drug delivery to the lungs: Methods and applications in oncology.
Man F; Tang J; Swedrowska M and 2 more (2022) - Transparency Score: 3/6
In vivo fate and intracellular trafficking of vaccine delivery systems.
Lee J; Kim D; Byun J and 3 more (2022) - Transparency Score: 3/6
Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases.
Aldarondo D; Wayne E. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"This work was supported by the Cystic Fibrosis Research Trust (SF) and a Wellcome Trust Senior Clinical Fellowship (EWFWA). The authors are members of the UK Cystic Fibrosis Gene Therapy Consortium (www.cfgenetherapy.org.uk)."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025